Larry Gold is the Founder of SomaLogic, and is a Professor at the University of Colorado Boulder. Larry also serves on the Board of Directors of BioForce Nanosystems, BT Pharma, CompleGen, MicroPhage and the Scientific Advisory Board of Archemix. Prior to SomaLogic, he also founded NeXagen, Inc., which later became NeXstar Pharmaceuticals, Inc., then merged with Gilead Sciences, Inc. to form a global organization committed to the discovery, development and commercialization of novel products that treat infectious diseases. During nearly 10 years at NeXstar, he held numerous executive positions including Chairman of the Board, Executive VP of R&D, and Chief Science Officer. He also co-founded and served as co-Director of Research at Synergen, Inc., a pioneering biotechnology company later acquired by Amgen, Inc. Larry has received many citations including the CU Distinguished Lectureship Award, the National Institutes of Health Merit Award, the Career Development Award, and the Chiron Prize for Biotechnology. In addition, He is a member of the American Academy of Arts and Sciences and the National Academy of Sciences. Larry earned his Ph.D. from the University of Connecticut and completed his post-doctoral studies at the Rockefeller University.